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Socioeconomic Costs of Overweight and Obesity in Korean Adults
This study was conducted to estimate the socioeconomic costs of overweight and obesity 
in a sample of Korean adults aged 20 yr and older in 2005. The socioeconomic costs of 
overweight and obesity include direct costs (inpatient care, outpatient care and 
medication) and indirect costs (loss of productivity due to premature deaths and inpatient 
care, time costs, traffic costs and nursing fees). Hypertension, diabetes mellitus, 
dyslipidemia, ischemic heart disease, stroke, colon cancer and osteoarthritis were selected 
as obesity-related diseases. The population attributable fraction (PAF) of obesity was 
calculated from national representative data of Korea such as the National Health 
Insurance Corporation (NHIC) cohort data and the 2005 Korea National Health and 
Nutrition Examination Survey (KNHANES) data. Direct costs of overweight and obesity 
were estimated at approximately U$1,081 million equivalent (men: U$497 million, 
women: U$584 million) and indirect costs were estimated at approximately U$706 million 
(men: U$527 million, women: U$178 million). The estimated total socioeconomic costs of 
overweight and obesity were approximately U$1,787 million (men: U$1,081 million, 
women: U$706 million). These total costs represented about 0.22% of the gross domestic 
product (GDP) and 3.7% of the national health care expenditures in 2005. We found the 
socioeconomic costs of overweight and obesity in Korean adults aged 20 yr and older are 
substantial. In order to control the socioeconomic burden attributable to overweight and 
obesity, effective national strategies for prevention and management of obesity should be 
established and implemented. 
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INTRODUCTION
Obesity is a state of an excess of body fat that causes increased 
risk of metabolic derangement (1, 2). World Health Organiza-
tion (WHO) estimated that globally in 2005, approximately 1.6 
billion adults were overweight and at least 400 million adults 
were obese. They also predicted that by 2015, approximately 2.3 
billion adults would be overweight and more than 700 million 
would be obese. Obesity prevalence has been constantly increas-
ing in Korea, too. According to the Korea National Health and 
Nutrition Examination Survey (KNHANES) data, obesity (body 
mass index [BMI] ≥ 25 kg/m
2) prevalence in Korea increased 
from 26.3% (male, 25.0%; female, 27.0%) in 1998 to 31.7% (male, 
35.1%; female, 28.0%) in 2005. In 1997, WHO anticipated that 
obesity, along with smoking, would be the most serious public 
health problem, which threatens the health of world popula-
tion, in the 21st century (3). Must et al. (4) reported that the prev-
alence of obesity-related comorbidities such as type 2 diabetes 
mellitus, high blood pressure, and osteoarthritis, was increased 
along with increasing severity of overweight and obesity in adults 
aged 25 yr and older, who participated in the Third National 
Health and Nutrition Examination Survey (NHANES). The dis-
ease burden associated with obesity is not only a problem lim-
ited to Western developed countries anymore but has increased 
to a serious level also in Asia-Pacific countries including Korea. 
The Asia-Pacific Cohort Studies Collaboration reported that the 
population attributable fraction (PAF) of overweight and obesi-
ty ranged from 0.8%-9.2% for coronary heart disease mortality, 
0.2%-2.9% for hemorrhagic stroke mortality, and 0.9%-10.2% for 
ischemic stroke mortality in 14 Asia-Pacific countries (5). 
  Increase in the prevalence of obesity and obesity-related dis-
eases leads to the growth of socioeconomic burden. According 
to previous studies, patients with obesity had 25%-52% higher 
medical care costs than normal-weighted individuals (6-8). Med-
ical care costs attributable to obesity was reported to account 
for 2.0%-7.0% of national health care expenditures in Western 
developed countries (9). The direct costs for obesity in the USA 
in 1995 were estimated to be approximately 70 billion US dol-
lars, which exceeded estimates of the direct costs for coronary 
artery disease, hypertension and diabetes mellitus (10). Accord-
ing to a study in Sweden, the obese women had 1.5-1.9 times 
higher sick-leave during 1 yr compared to the general Swedish 
women. And, approximately 10% of the total cost of loss of pro-
ductivity due to sick-leave and disability pensions in Swedish 
women was related to obesity and obesity-related diseases (11). 
Obesity also brings about premature death and disability, which Kang JH, et al.  •  Socioeconomic Costs of Obesity
1534   http://jkms.org http://dx.doi.org/10.3346/jkms.2011.26.12.1533
lead to loss of labor productivity (12, 13). Popkin et al. (14) esti-
mated the indirect costs of obesity due to premature death, pre-
mature disability and sick-leave in China in 2000 to be 43.6 bil-
lion US dollars (3.58% of the gross national product [GNP]).
  The socioeconomic costs of obesity in Korean adults were first 
estimated by Jeong et al. (15) using 1998 KNHANES data. They 
reported that the estimated costs attributable to obesity in Korea 
ranged from U$170 million equivalent to $350 million (exchange 
rate in 1998: 1,209 Korean Won for 1 US dollar), which were con-
siderably smaller than those in Western developed countries. 
However, because the prevalences of obesity and obesity-relat-
ed diseases in Korea have been constantly increasing, the socio-
economic costs of obesity in Korean adults are anticipated to 
have increased rapidly as well. Yet, there has been no study on 
this issue in Korea since 1998. Thus, this study was conducted 
to estimate the socioeconomic costs attributable to overweight 
and obesity in Korean adults in 2005, in which KNHANES was 
most recently carried out. 
MATERIALS AND METHODS
Selection of obesity-related diseases
We selected hypertension (ICD-10 code: I10), diabetes mellitus 
(E10-E14), dyslipidemia (E78), ischemic heart disease (I20-I25), 
stroke (I60-I64), breast cancer (C50), colon cancer (C18-C21) 
and osteoarthritis (M15-M19) as obesity-related diseases be-
cause previous studies (9) demonstrated that obesity has the 
etiological role on these diseases and these diseases were also 
investigated in 2005 KNHANES. However, breast cancer was 
excluded from obesity-related diseases because relative risk of 
obesity on breast cancer was not high. 
Calculation of population attributable fraction (PAF)
We used the PAF of obesity in order to allocate the proportion 
attributable to obesity in the total costs of obesity-related dis-
eases. The PAF of obesity is calculated using the formula; PAF =  
P × (RR-1)/[P × (RR-1) + 1], where P is the prevalence of over-
weight and obesity and RR is the relative risk of overweight and 
obesity on obesity-related diseases. That is, the PAF of obesity is 
explained by the prevalence of obesity and the relative risk of 
obesity. The RRs and PAFs of obesity on obesity-related diseas-
es in male and female were presented in Table 1 and 2. 
Prevalence of obesity
The prevalence of obesity in Korean adults aged 20 yr and older 
was obtained from the raw data of 2005 KNHANES, to which was 
applied the weight value. We defined BMI of 18.5-22.9 kg/m
2 as 
normal weight, 23-24.9 kg/m
2 as overweight, 25-29.9 kg/m
2 as 
Table 1. RR and PAF on obesity-related diseases of obesity status (men)
Diseases BMI (kg/m
2)
Inpatient care Outpatient care Total
RR (95% CI) PAF RR (95% CI) PAF RR (95% CI) PAF
Hypertension  23-24.9
 25-29.9
≥ 30
 Subtotal
1.299 (1.135-1.485)
2.072 (1.830-2.345)
2.830 (1.944-4.120)
0.062
0.209
0.059
0.329
1.513 (1.488-1.539)
2.078 (2.045-2.112)
3.203 (3.054-3.360)
0.101
0.209
0.070
0.381
1.506 (1.482-1.532)
2.068 (2.036-2.102)
3.179 (3.033-3.332)
0.100
0.208
0.070
0.378
Diabetes mellitus  23-24.9
 25-29.9
≥ 30
 Subtotal
1.276 (1.119-1.456)
1.909 (1.689-2.158)
4.878 (3.697-6.435)
0.057
0.183
0.117
0.357
1.410 (1.373-1.447)
1.916 (1.869-1.964)
3.297 (3.081-3.529)
0.083
0.184
0.073
0.340
1.406 (1.371-1.443)
1.901 (1.855-1.948)
3.300 (3.087-3.527)
0.082
0.181
0.073
0.336
Ischemic heart disease  23-24.9
 25-29.9
≥ 30
 Subtotal
1.241 (1.173-1.312)
1.444 (1.366-1.526)
2.065 (1.749-2.439)
0.050
0.098
0.035
0.184
1.174 (1.143-1.206)
1.347 (1.311-1.383)
1.574 (1.437-1.724)
0.037
0.079
0.019
0.135
1.173 (1.142-1.204)
1.347 (1.312-1.383)
1.585 (1.451-1.732)
0.037
0.079
0.020
0.135
Stroke  23-24.9
 25-29.9
≥ 30
 Subtotal
1.102 (1.034-1.174)
1.190 (1.116-1.269)
1.575 (1.281-1.938)
0.022
0.045
0.019
0.086
1.138 (1.093-1.185)
1.274 (1.224-1.327)
1.455 (1.265-1.673)
0.029
0.063
0.015
0.108
1.134 (1.091-1.179)
1.261 (1.213-1.311)
1.482 (1.298-1.692)
0.029
0.060
0.016
0.105
Colon cancer  23-24.9
 25-29.9
≥ 30
 Subtotal
1.209 (1.091-1.340)
1.265 (1.140-1.404)
1.314 (0.895-1.929)
0.044
0.061
-
0.105
1.129 (1.041-1.226)
1.196 (1.101-1.299)
1.405 (1.053-1.874)
0.028
0.046
0.014
0.087
1.098 (1.041-1.159)
1.133 (1.073-1.197)
1.152 (0.936-1.418)
0.021
0.032
-
0.053
Osteoarthritis  23-24.9
 25-29.9
≥ 30
 Subtotal
1.247 (1.039-1.497)
1.804 (1.521-2.141)
3.205 (2.031-5.057)
0.052
0.165
0.070
0.287
1.106 (1.090-1.122)
1.207 (1.189-1.224)
1.317 (1.248-1.389)
0.023
0.048
0.011
0.082
1.105 (1.089-1.121)
1.205 (1.187-1.222)
1.315 (1.247-1.387)
0.023
0.048
0.011
0.081
Dyslipidemia  23-24.9
 25-29.9
≥ 30
 Subtotal
1.504 (1.104-2.049)
1.637 (1.200-2.234)
1.505 (0.475-4.768)
0.100
0.135
-
0.235
1.379 (1.343-1.416)
1.643 (1.601-1.686)
2.048 (1.884-2.226)
0.077
0.136
0.035
0.248
1.391 (1.356-1.428)
1.663 (1.622-1.706)
2.061 (1.900-2.236)
0.079
0.140
0.035
0.255
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obesity I and over 30 kg/m
2s as obesity II. These BMI cut-offs 
were recommended for Asians by WHO (16). In this study, 27.4% 
of men and 22.0% of women were diagnosed as overweight, 
31.5% of men and 24.6% of women as obese I, 3.6% of men and 
3.4% of women as obese II.
  PAFs of overweight, obesity I and obesity II were calculated 
separately and the sum of calculated PAFs was presented as the 
total PAF of obesity on obesity-related diseases. 
Relative risk
The data source for calculation of the RR was the National Health 
Insurance Corporation (NHIC) cohort data. NHIC provides bi-
ennial health examinations to the entire Korean population aged 
40 yr and older. The NHIC cohort was composed of the partici-
pants of health examinations of NHIC performed in 2000 who 
repeatedly participated in health examinations in 2002 or 2004. 
Subjects, who did not have any previous history of obesity-relat-
ed diseases and were judged as healthy men in 2000, were only 
enrolled in this study. Subjects who had problem in qualifica-
tion as insured persons or who had some errors in computer-
ized data, were excluded additionally. The payment data to them 
by NHIC from 1999 to 2006 was obtained. The total number of 
the participants of health examinations of NHIC was 5,099,737. 
Among them, 3,026,483 and 2,958,706 individuals were again 
undergone health examinations in 2002 and in 2004, respective-
ly. Finally, 1,910,194 individuals were included in this study 
(men, 65.4%; women, 34.5%).
  The RRs of overweight, obesity I and obesity II were estimated 
using the Cox proportional hazard model upon the first occur-
rence of payment for outpatient care, inpatient care and either, 
respectively. Each RR was adjusted for age, smoking status, al-
cohol consumption, frequency of meat intake, exercise, family 
medical history, household income, diabetes mellitus, hyper-
tension, hypercholesterolemia, and so on. If any RRs of obesity 
on obesity-related diseases were interpreted as statistically in-
significant, they were not included in calculation of PAF. 
Estimation of costs
The socioeconomic costs of obesity can include direct costs, in-
direct costs and intangible costs. Intangible costs such as pain, 
suffering and decreased quality of life, which are very important 
problems to patients, are omitted in most studies on cost of ill-
Table 2. RR and PAF on obesity-related diseases of obesity status (women)
Diseases BMI (kg/m
2)
Inpatient care Outpatient care Total
RR (95% CI) PAF RR (95% CI) PAF RR (95% CI) PAF
Hypertension  23-24.9
 25-29.9
≥ 30
 Subtotal
  1.405 (1.164-1.695)
  1.831 (1.534-2.185)
  2.546 (1.740-3.723)
0.082
0.170
0.050
0.302
1.434 (1.400-1.468)
1.916 (1.873-1.959)
2.797 (2.665-2.935)
0.087
0.184
0.058
0.329
1.424 (1.391-1.457)
1.896 (1.854-1.938)
2.783 (2.654-2.918)
0.085
0.180
0.058
0.324
Diabetes mellitus  23-24.9
 25-29.9
≥ 30
 Subtotal
  1.354 (1.068-1.716)
  2.345 (1.906-2.886)
  5.188 (3.705-7.264)
0.072
0.248
0.126
0.446
1.333 (1.283-1.386)
1.838 (1.773-1.906)
2.747 (2.554-2.955)
0.068
0.171
0.057
0.296
1.336 (1.286-1.388)
1.828 (1.764-1.894)
2.727 (2.537-2.930)
0.069
0.169
0.056
0.294
Ischemic heart disease  23-24.9
 25-29.9
≥ 30
 Subtotal
  1.300 (1.172-1.441)
  1.406 (1.270-1.556)
  1.765 (1.409-2.210)
0.062
0.091
0.026
0.178
1.186 (1.139-1.235)
1.295 (1.244-1.348)
1.494 (1.357-1.645)
0.039
0.068
0.017
0.124
1.188 (1.142-1.236)
1.295 (1.245-1.347)
1.510 (1.375-1.657)
0.040
0.068
0.017
0.125
Stroke  23-24.9
 25-29.9
≥ 30
 Subtotal
  1.127 (1.030-1.234)
  1.136 (1.039-1.241)
  1.438 (1.175-1.760)
0.027
0.032
0.015
0.074
1.122 (1.063-1.185)
1.198 (1.136-1.263)
1.246 (1.093-1.420)
0.026
0.046
0.008
0.081
1.125 (1.068-1.185)
1.199 (1.140-1.262)
1.244 (1.098-1.410)
0.027
0.047
0.008
0.082
Colon cancer  23-24.9
 25-29.9
≥ 30
 Subtotal
  1.157 (1.968-1.384)
  1.231 (1.033-1.468)
 1.735* (0.412-1.310)
-
0.054
-
0.054
1.027 (0.897-1.175)
1.028 (0.898-1.177)
0.618 (0.391-0.977)
-
-
-
-
1.089 (1.026-1.155)
1.018 (0.957-1.083)
0.912 (0.765-1.089)
0.019
-
-
0.019
Breast cancer  23-24.9
 25-29.9
≥ 30
 Subtotal
  0.982 (0.870-1.109)
  0.908 (0.797-1.034)
  0.697 (0.460-1.057)
-
-
-
-
1.031 (0.936-1.136)
0.927 (0.834-1.029)
0.695 (0.496-0.973)
-
-
-
-
1.023 (0.930-1.126)
0.914 (0.824-1.014)
0.694 (0.498-0.967)
-
-
-
-
Osteoarthritis  23-24.9
 25-29.9
≥ 30
 Subtotal
  1.308 (1.111-1.541)
  2.375 (2.060-2.738)
  5.710 (4.531-7.195)
0.064
0.253
0.139
0.455
1.196 (1.177-1.215)
1.441 (1.419-1.464)
1.870 (1.800-1.942)
0.041
0.098
0.029
0.168
1.195 (1.177-1.214)
1.439 (1.417-1.461)
1.863 (1.794-1.935)
0.041
0.097
0.029
0.167
Dyslipidemia  23-24.9
 25-29.9
≥ 30
 Subtotal
  1.298 (0.745-2.260)
  1.633 (0.968-2.755)
  1.824 (0.552-6.022)
-
-
-
-
1.221 (1.180-1.263)
1.425 (1.379-1.473)
1.551 (1.431-1.681)
0.046
0.095
0.019
0.160
1.231 (1.191-1.272)
1.432 (1.387-1.479)
1.621 (1.500-1.751)
0.048
0.096
0.021
0.165
PAF, population attributable fraction; RR, relative risk; CI, confidence interval.Kang JH, et al.  •  Socioeconomic Costs of Obesity
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ness because it is difficult to quantify these costs in monetary 
terms. These costs were not included in this study. Direct costs 
include hospitalization, outpatient visits and medication for the 
purpose of prevention and treatment of obesity and obesity-re-
lated diseases. However, it is quite difficult to estimate precisely 
the costs for management of obesity itself, which is not covered 
by the national health insurance in Korea and is done in outside 
of the formal health care system. Costs for management of obe-
sity-related diseases were only included as direct costs in this 
study. Loss of productivity due to premature deaths and admis-
sion, time costs, traffic costs and nursing fees were measured as 
indirect costs in this study.
Direct costs
Direct costs were composed of costs for inpatient care, outpa-
tient care and medication. They were calculated from the pay-
ment data of NHIC, 2005 using formula 1. Costs, not insured by 
NHIC, were not included in these data. So, the proportion of not-
insured, self-imposed costs in 2005, which was reported in an 
investigation (17), was reflected in this study. However, the pro-
portions of not-insured, self-imposed costs on all obesity-relat-
ed diseases were not reported in the investigation. Those were 
substituted with the average proportion of not-insured, self-im-
posed costs on all the investigated diseases. The proportions of 
not-insured, self-imposed costs for medication were totally ap-
plied by the average proportion of not-insured, self-imposed 
costs for the all investigated medication because those were not 
investigated separately for each disease. 
     Formula 1) Direct costs 
     = (ΣHij × PAFij)/(1-αi) 
     i = 1,2,….,n
th disease
     j = 1 if male, 2 if female 
     Hij = Costs for inpatient care, outpatient care or medication  
                        to treat ‘i’ disease in ‘j’ sex
     PAFij = population attributable fraction of obesity on ‘i’ disease  
                            in ‘j’ sex 
     α = the proportion of not-insured, self-imposed costs on the
                     ‘i’ disease
Indirect costs: Loss of productivity due to premature deaths 
Costs by premature deaths due to obesity-related diseases were 
estimated by calculation of present value of lost future earning 
via formula 2. According to the data of the Korea National Sta-
tistical Office, total 56,633 individuals died of all obesity-related 
diseases in adults aged 20 yr and older in 2005 (18). The number 
of death attributable to obesity was calculated through multipli-
cation the number of deaths due to each obesity-related disease 
by total PAF for each disease. Future earnings were calculated 
within wages and future earnings after 2005 were assumed to be 
the same as 2005. In addition, future earnings were discounted 
to the present values by the rate of 6%. The discount rate of 6% 
has been used generally in healthcare project (19). The average 
monthly wage income of Korean adults aged 20 yr and older in 
2005 was U$ 2,084 men and U$1,383 for women (exchange rate 
in 2005: 1,013 Korean Won for 1 US dollar). Labor force partici-
pation rate and employment rate were 80.3% and 96.1% for men 
and 53.1% and 96.7% for women, respectively (20). 
     Formula 2) Loss of productivity due to premature deaths
     = (Ij × ΣPAMij × Pj × Ej)/(1 + r)
n 
     Ij = Average annual wage income of ‘j’ sex
     PAMij = Number of death attributable to obesity via ‘i’ disease 
                              in ‘j’ sex
     Pj = Labor force participation rate of ‘j’ sex 
     Ej = Employment rate of ‘j’ sex 
     r = The discount rate 
     n = Expected years of life lost
Indirect costs: Loss of productivity due to inpatient care 
Loss of productivity due to hospitalization was calculated with 
days of inpatient care due to each obesity-related disease and the 
average daily wage income via formula 3. Total number of days 
of inpatient care due to all obesity-related diseases in adults aged 
20 yr and older was approximately 7.88 million days in 2005. The 
average daily wage income of Korean adults aged 20 yr and old-
er in 2005 was U$ 83 equivalent for men and U$55 for women.
     Formula 3) Loss of productivity due to inpatient care
     = Ijd × ΣNij × Dij × PAFij × Pj × Ej 
     Ijd = Average daily wage income of ‘j’ sex
     Nij = Total number of case of inpatient care with ‘i’ disease in  
                      ‘j’ sex
     Dij = Average days per case of inpatient care with ‘i’ disease in  
                      ‘j’ sex
Indirect costs: Time costs
Time costs were calculated with time spent for hospital admis-
sion and outpatient treatment and the average wage income per 
minute via formula 4. Time spent for hospital admission for each 
disease in each sex was investigated in 2005 KNHANES. Time 
spent for outpatient treatment included time spent for visiting 
physician, waiting time for outpatient treatment and treating 
time. In 2005 KNHANES, time spent for visiting physician was 
investigated, but the others were not investigated. So, waiting 
time for outpatient treatment was substituted with data investi-
gated in 1998 KNHANES and treating time was assumed to be 3 
min. The average wage income per minunte of Korean adults 
aged 20 yr and older in 2005 was U$ 0.17 for men and U$ 0.12 Kang JH, et al.  •  Socioeconomic Costs of Obesity
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for women.
     Formula 4) Time costs
     = [(MINinij × ΣNij) + (MINonij × ΣOij)] × Ijm × PAFij × Pj × Ej 
     MINinij = minutes spent per hospital admission with ‘i’ disease  
                                  in ‘j’ sex
    MINonij = minutes spent per outpatient treatment with ‘i’ dis 
                                    ease in ‘j’ sex
     Oij = Total number of case of outpatient care with ‘i’ disease in 
                       ‘j’ sex
     Ijm = Average wage income per minute of ‘j’ sex
Indirect costs: Traffic costs
The traffic costs included two-way traffic costs of outpatients, 
inpatients and caregivers of inpatients and were calculated via 
formula 5. In 2005 KNHANES, two-way traffic costs of outpa-
tients and inpatients were investigated, but the other was not 
investigated. So, those of caregivers of inpatients was substituted 
with adjusted values, investigated in 1995 Korea National Health 
Examination & Health Behavior Survey, by 1.7, the increase rate 
of traffic fee during 10 yr. 
     Formula 5) Traffic costs
     = (TCon × ΣOij) × PAFij + [(TCin + TCcg) × ΣNij] × PAFij 
     TCon = Average two-way transportation costs of outpatients 
     TCin = Average two-way transportation costs of inpatients 
     TCcg = Average two-way transportation costs of caregivers of  
                             inpatients
Indirect costs: Nursing fees 
The nursing fees were investigated in 2005 KNHANES and were 
calculated via formula 6. It was investigated in 2005 KNHANES 
that nursing fees were paid only in colon cancer (U$ 340) in men, 
and stroke (U$ 877), colon cancer (U$ 237), and osteoarthritis 
(U$ 494) in women.
     Formula 6) Nursing fees 
     = ΣNij × NCij × PAFij 
     NCij = Average nursing costs per case of inpatient care with ‘i’  
                           disease in ‘j’ sex 
RESULTS 
Direct costs 
Costs for inpatient care attributable to overweight and obesity 
in Korean adults aged 20 yr and older were estimated (Table 3) 
at about U$265 million equivalent (men, U$108 million; women, 
U$157 million). Inpatient care cost for ischemic heart disease 
occupied the largest proportion in these costs in men and inpa-
tient care cost for osteoarthritis did in women. The estimated 
costs for outpatient care attributable to overweight and obesity 
were approximately U$300 million equivalent (men, U$133 mil-
lion; women, U$167 million). Costs for medication attributable 
to overweight and obesity were estimated to be approximately 
U$516 million (men, U$256 million; women, U$260 million). 
Hypertension made the largest contribution to costs for both out-
patient care cost and medication attributable to overweight and 
obesity in both sexes. The total direct costs of overweight and 
obesity were estimated at about U$1,081 million (men, U$497 
million; women, U$584 million). The direct costs of overweight 
and obesity due to hypertension were the highest in both sexes. 
Costs for medication attributable to overweight and obesity were 
larger than costs for inpatients care or outpatient care. 
Indirect costs 
Loss of productivity due to premature deaths attributable to over-
weight and obesity was estimated (Table 4) at approximately 
U$444 million (men, U$374 million; women, U$70 million). Di-
abetes mellitus were the most important pathway of costs due 
to obestiy-attributed premature deaths in both sexes. The esti-
mated amount of loss of productivity due to hospitalization at-
tributable to overweight and obesity obesity-related diseases 
was approximately U$74 million (men, U$44 million; women, 
U$29 million). Hospitalization due to diabetes mellitus was the 
Table 3. Direct costs of obesity                                                                                                                                                                              (unit: U$1,000 equivalent)
Diseases
Inpatient care Outpatient care Pharmaceuticals Total
Men Women Total Men Women Total Men Women Total Men Women Total
HTN   3,459   5,423   8,882  68,346  82,389 150,734 143,507 153,026 296,533 215,312 240,837  456,149
DM  21,424  26,040  47,465  44,559  37,034  81,592  81,701  71,523 153,224 147,684 134,596  282,281
OA   6,977  77,764  84,742   5,585  38,142  43,728   1,844  15,810  17,654  14,407 131,717  146,123
IHD  42,139  24,156  66,295   4,751   3,716   8,466  12,924   8,464  21,388  59,813  36,336   96,149
Stroke  21,673  19,694  41,367   4,163   2,944   7,107   9,149   6,123  15,272  34,985  28,761   63,746
Colon cancer  12,095  4,175  16,269   2,705      0   2,705   1,010      0   1,010  15,809   4,175   19,984
Dyslipidemia     75      0     75   3,086   2,535   5,621   5,758   5,037  10,795   8,919   7,572   16,491
Total 107,842 157,252 265,094 133,194 166,758 299,953 255,892 259,984 515,877 496,930 583,994 1,080,923
HTN, hypertension; DM, diabetes mellitus; IHD, ischemic heart disease; OA, osteoarthritis.Kang JH, et al.  •  Socioeconomic Costs of Obesity
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most important cause of these costs in men and hospitalization 
due to stroke was in women. Time costs attributable to obesity 
was estimated to be about U$70 million (men, U$46 million; 
women, U$24 million) and transportaion costs attributable to 
overweight and obesity were estimated to be approximately 
U$103 million (men, U$62 million; women, U$41 million). Hy-
pertension made the largest contribution to time costs of over-
weight and obestiy and diabetes mellitus most largely contrib-
uted to transportation costs of overweight and obesity. Nursing 
fees attributable to overweight and obesity were estimated at 
about U$16 million (men, U$2 million; women, U$14 million). 
The total indirect costs of overweight and obesity were estimat-
ed to be approximately U$706 million (men, U$527 million; 
women, U$178 million). The indirect costs of overweight and 
obesity due to diabetes mellitus were the highest in both sexes. 
The indirect costs of overweight and obesity were larger in men 
than in women.
Total socioeconomic costs
The estimated total socioeconomic costs of overweight and obe-
sity in Korean adults aged 20 yr and older were approximately 
U$1,787 million equivalent (men, U$1,081 million; women, U$706 
million). Costs for diabetes mellitus occupied the largest propor-
tion in the total costs attributable to overweight and obesity in 
Table 4. Indirect costs of obesity                                                                                                                                                                            (unit: U$1,000 equivalent)
Diseases
Loss of productivity  
due to  
premature deaths
Loss of productivity  
due to admission
Time costs  Traffic costs Nursing fees Total
Men
   HTN
   DM
   IHD
   Stroke
   Colon cancer
   OA
   Dyslipidemia 
   Subtotal
 
 14,692
179,821
 73,022
 90,939
 15,057
19
   312
373,863
  
  7,378
 17,983
  4,659
  8,980
  2,769
  2,037
   564
 44,369
  
 25,666
 15,826
  1,609
   622
   173
  1,055
   938
 45,889
  
 11,798
 38,302
  6,103
  2,107
  1,255
   895
  1,184
 61,644
  
     0
     0
     0
     0
  1,670
     0
     0
  1,670
  
 59,534
251,934
 85,393
102,649
 20,924
  4,005
  2,997
527,435
Women
   HTN
   DM
   IHD
   Stroke
   Colon cancer
   OA
   Dyslipidemia
   Subtotal
  
  4,605
 29,598
 13,224
 20,514
  1,678
    89
    14
 69,723
  
  3,014
  7,749
   675
    10
   472
  7,431
     0
 29,471
  
 14,120
  5,203
   444
   373
     7
  3,549
   408
 24,104
  
 12,080
 17,551
  2,162
  2,201
   420
  6,066
   701
 41,181
  
     0
     0
     0
  6,450
   415
  7,113
     0
  13,978
  
 33,819
 60,102
 16,506
 39,667
  2,990
 24,248
  1,122
178,456
Total
   HTN
   DM
   IHD
   Stroke
   Colon cancer
   OA
   Dyslipidemia
   Subtotal
  
 19,297
209,421
 86,247
111,453
 16,735
   108
   326
443,585
  
 10,392
 25,732
  5,335
 19,109
  3,241
  9,468
   564
 73,840
  
 39,787
 21,030
  2,053
   996
   179
  4,604
  1,345
 69,993
 
 23,878
 55,853
  8,266
  4,309
  1,673
  6,961
  1,885
102,823
 
     0
     0
     0
  6,450
2,086
7,113
0
15,649
 
 93,353
312,036
101,899
142,316
 23,914
 28,253
  4,119
705,891
HTN, hypertension; DM, diabetes mellitus; IHD, ischemic heart disease; OA, osteoarthritis.
Table 5. Total socioeconomic costs of obesity                                                                                                                                                         (unit: U$1,000 equivalent)
Diseases
Direct cost Indirect cost Total
Men Women Total Men Women Total Men Women Total
DM  147,684  134,596  282,281  251,934   60,102  312,036  399,618  194,698  594,317
HTN  215,312  240,837  456,149   59,534   33,819   93,353  274,846  274,656  549,502
Stroke   34,985   28,761   63,746  102,649   39,667  142,316  137,634   68,428  206,062
IHD   59,813   36,336   96,149   85,393   16,506  101,899  145,206   52,842  198,047
OA   14,407  131,717  146,123    4,005   24,248   28,253   18,413  155,964  174,377
Colon cancer   15,809    4,175   19,984   20,924    2,990   23,914   36,733    7,166   43,899
Dyslipidemia    8,919    7,572   16,491    2,997    1,122    4,119   11,915    8,694   20,610
Subtotal  496,930  583,994 1,080,923  527,435  178,456  705,891 1,024,364  762,449 1,786,814
HTN, hypertension; DM, diabetes mellitus; IHD, ischemic heart disease; OA, osteoarthritis.Kang JH, et al.  •  Socioeconomic Costs of Obesity
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men and costs for hypertension did in women (Table 5). The es-
timated total socioeconomic costs of obesity in Korean adults 
aged 20 yr and older were approximately U$1,306 million and 
those of overweight were approximately U$481 million (Table 6). 
 
DISCUSSION
This study estimated the socioeconomic costs of overweight and 
obesity in Korean adults aged 20 yr and older in 2005. The esti-
mated total costs were approximately U$1.8 billion equivalent 
(direct costs: U$1.1 billion, indirect costs: U$0.7 billion). These 
total costs represented about 0.22% of the gross domestic product 
(GDP) and 3.7% of the national health care expenditures in 2005. 
Diabetes mellitus and hypertension were the two main contrib-
utors to the socioeconomic costs of overweight and obesity.
  A previous study (15) on the same issue presented that the 
socioeconomic cost of overweight and obesity (BMI ≥ 23 kg/m
2) 
in Korean adults in 1998 were approximately U$350 million 
equivalent (0.094% of GDP, 1.88% of the total national health 
care expenditures). The socioeconomic costs of overweight and 
obesity has increased 4-5 times during these 7 yr. Even if the 
growth of GDP and the national health care expenditures in 
Korea was considered, increase of these costs was more than 2 
times. It is thought that the rapid increase in the prevalence of 
obesity in Korea has led to the increase of the socioeconomic 
costs attributable to obesity.
  According to a previous study (9), obesity accounts for 5.5%-
7.0% of national health care expenditures in the USA and 2.0%-
3.5% in other Western developed countries. The estimated med-
ical-care costs attributable to obesity were approximately 2.3% 
of the national health-care expenditures, which were similar to 
those in other Western developed countries than the USA. These 
results imply that the economic burden attributable to obesity 
in Korea is getting bigger like Western countries. 
  The socioeconomic costs of obesity can be classified into tan-
gible costs and intangible costs. Intangible costs are very impor-
tant problems to patients such as pain, suffering, and anxiety 
and are usually measured in terms of quality of life. Although 
there are several studies (21-23) that estimated intangible costs 
of diseases, these costs are omitted in most studies on cost of 
illness because it is difficult to quantify these costs in monetary 
terms. For estimation of intangible costs, organized and metic-
Table 6. Total socioeconomic costs of obesity by obesity grade                                                                                                                                (unit: U$1,000 equivalent)
Obesity grade
Direct cost Indirect cost Total
Men Women Total Men Women Total Men Women Total
Overweight 129,081  141,443  270,514  139,168  70,839  210,007  268,249 212,282 480,521
Obesity I 272,327  327,874  600,208  293,380  83,142  376,522  565,707 411,016 976,730
Obesity II 95,522  114,677  210,201  94,887  24,475  119,362  190,410 139,151 329,563
Subtotal 496,930  583,994  1,080,923  527,435  178,456  705,891  1,024,365 762,450 1,786,814
Overweight, 23-24.9 kg/m
2; Obesity I, 25-29.9 kg/m
2; Obesity II,  ≥ 30 kg/m
2.
ulous investigation on the quality of life of study subjects should 
be planned. However, because this study was made of second-
ary data, intangible costs could not be included in this study.
  The medical care costs attributable to obesity can be classi-
fied into costs for management of obesity-related diseases and 
costs for management of obesity itself. And, these costs can be 
divided into costs expended within the formal health care sys-
tem and costs expended in outside of the formal health care 
system, respectively. Costs for management of obesity itself is 
rapidly increasing in Korea. The amount of sales of anti-obesity 
drugs has increased from U$60 million equivalent in 2005 to 
U$81 million in 2007 (exchange rate in 2007, 938 Korean Won 
for 1 US dollar) in Korea (22). However, management of obesity 
is not covered by the national health insurance in Korea and a 
lot of Koreans utilize services for weight loss in outside of the 
formal health care system. Therefore, data on the costs for man-
agement of obesity itself could not be obtained. Besides the dis-
eases defined as obesity-related diseases in this study, various 
diseases including gallbladder disease and endometrial cancer 
can be considered as obesity-related diseases. However, only dis-
eases investigated in 2005 KNHANES were selected as obesity-
related diseases in this study. These limitations of study meth-
ods made the socioeconomic cost of overweight and obesity 
underestimated in this study. Therefore, it is thought that the 
real costs of obesity may be superior to U$1.8 billion equivalent, 
the estimated cost of obesty of this study. That PAF of obesity 
was calculated from national representative data such as NHIC 
cohort data and 2005 KNHANES data, is one of strengths of this 
study. The PAF of obesity calculated in this study can be utilized 
in researches on the relationship between obesity and obesity-
related diseases in Asian including Korean. 
  We found the socioeconomic costs of overweight and obesity 
in Korean adults aged 20 yr and older were substantial. Also, this 
study showed the socioeconomic burden of obesity (U$1,306 
million equivalent) was much bigger than that of overweight 
(U$481 million). This study might be a good evidence for bene-
fits of prevention and management of obesity. In order to con-
trol the socioeconomic burden attributable to overweight and 
obesity, effective national strategies for prevention and manage-
ment of obesity should be established and implemented. The 
results of this study are expected to make a contribution to plan 
and execution of obesity-related public health policy. Kang JH, et al.  •  Socioeconomic Costs of Obesity
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